Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


J&J Finds Silver Lining in CMS Reimbursement Decision On ESAs

This article was originally published in The Pink Sheet Daily

Executive Summary

Although disappointing, the CMS decision to eliminate Medicare reimbursement for some ESA uses has created an environment of greater certainty for planning purposes, J&J exec says.

You may also be interested in...

FDA Calls Medicare ESA Coverage Decision “Generally Consistent” With Labeling

FDA acknowledges confusion with dosing recommendations that it aims to clarify in revised labeling, agency advises Reps. Waxman and Stark.

Committee Rejects FDA’s Proposed Treatment Target For ESAs

Hemoglobin target will depend on FDA’s acceptance of observational data to drive treatment.

Amgen Restructures Amid Anemic Aranesp Sales

Biotech will eliminate up to 2,600 jobs, prioritize R&D spend to achieve $1 billion to $1.3 billion in pre-tax savings.

Related Content





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts